These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33996265)

  • 1. PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy.
    Zahm CD; Moseman JE; Delmastro LE; G Mcneel D
    Oncoimmunology; 2021 Apr; 10(1):1912892. PubMed ID: 33996265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of PD-1 and LAG-3 Immune Checkpoints Combined with Vaccination Restores the Function of Antiviral Tissue-Resident CD8
    Roy S; Coulon PG; Prakash S; Srivastava R; Geertsema R; Dhanushkodi N; Lam C; Nguyen V; Gorospe E; Nguyen AM; Salazar S; Alomari NI; Warsi WR; BenMohamed L
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31217250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade.
    Principe N; Phung AL; Stevens KLP; Elaskalani O; Wylie B; Tilsed CM; Sheikh F; Orozco Morales ML; Kidman J; Marcq E; Fisher SA; Nowak AK; McDonnell AM; Lesterhuis WJ; Chee J
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39343508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy.
    Jeon D; Hill E; Moseman JE; McNeel DG
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen-loaded Monocyte Administration and Flt3 Ligand Augment the Antitumor Efficacy of Immune Checkpoint Blockade in a Murine Melanoma Model.
    D'Anniballe VM; Huang MN; Lueck BD; Nicholson LT; McFatridge I; Gunn MD
    J Immunother; 2023 Nov-Dec 01; 46(9):333-340. PubMed ID: 37737688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.
    Peng S; Tan M; Li YD; Cheng MA; Farmer E; Ferrall L; Gaillard S; Roden RBS; Hung CF; Wu TC
    Cancer Immunol Immunother; 2021 Apr; 70(4):1049-1062. PubMed ID: 33108473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses.
    Furtado R; Chorro L; Zimmerman N; Guillen E; Spaulding E; Chin SS; Daily JP; Lauvau G
    Front Immunol; 2020; 11():576743. PubMed ID: 33519801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.
    Lichtenegger FS; Rothe M; Schnorfeil FM; Deiser K; Krupka C; Augsberger C; Schlüter M; Neitz J; Subklewe M
    Front Immunol; 2018; 9():385. PubMed ID: 29535740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma.
    Zelba H; Bedke J; Hennenlotter J; Mostböck S; Zettl M; Zichner T; Chandran A; Stenzl A; Rammensee HG; Gouttefangeas C
    Cancer Immunol Res; 2019 Nov; 7(11):1891-1899. PubMed ID: 31484656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.
    Rekoske BT; Smith HA; Olson BM; Maricque BB; McNeel DG
    Cancer Immunol Res; 2015 Aug; 3(8):946-55. PubMed ID: 26041735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.
    Sung E; Ko M; Won JY; Jo Y; Park E; Kim H; Choi E; Jung UJ; Jeon J; Kim Y; Ahn H; Choi DS; Choi S; Hong Y; Park H; Lee H; Son YG; Park K; Won J; Oh SJ; Lee S; Kim KP; Yoo C; Song HK; Jin HS; Jung J; Park Y
    Mol Ther; 2022 Aug; 30(8):2800-2816. PubMed ID: 35526096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LAG-3 and PD-1 synergize on CD8
    Andrews LP; Butler SC; Cui J; Cillo AR; Cardello C; Liu C; Brunazzi EA; Baessler A; Xie B; Kunning SR; Ngiow SF; Huang YJ; Manne S; Sharpe AH; Delgoffe GM; Wherry EJ; Kirkwood JM; Bruno TC; Workman CJ; Vignali DAA
    Cell; 2024 Aug; 187(16):4355-4372.e22. PubMed ID: 39121848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human
    Burova E; Hermann A; Dai J; Ullman E; Halasz G; Potocky T; Hong S; Liu M; Allbritton O; Woodruff A; Pei J; Rafique A; Poueymirou W; Martin J; MacDonald D; Olson WC; Murphy A; Ioffe E; Thurston G; Mohrs M
    Mol Cancer Ther; 2019 Nov; 18(11):2051-2062. PubMed ID: 31395688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
    McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
    Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
    Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT.
    Duperret EK; Wise MC; Trautz A; Villarreal DO; Ferraro B; Walters J; Yan J; Khan A; Masteller E; Humeau L; Weiner DB
    Mol Ther; 2018 Feb; 26(2):435-445. PubMed ID: 29249395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8
    Zahm CD; Colluru VT; McNeel DG
    Cancer Immunol Res; 2017 Aug; 5(8):630-641. PubMed ID: 28634215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma.
    Kos S; Lopes A; Preat V; Cemazar M; Lampreht Tratar U; Ucakar B; Vanvarenberg K; Sersa G; Vandermeulen G
    PLoS One; 2019; 14(5):e0217762. PubMed ID: 31150505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses.
    Santos PM; Adamik J; Howes TR; Du S; Vujanovic L; Warren S; Gambotto A; Kirkwood JM; Butterfield LH
    J Exp Med; 2020 Jul; 217(7):. PubMed ID: 32369107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.